-
Phase 2 study with a long way to go suggests that a desert-toad-derived psychedelic drug in nasal spray format may provide relief for people with treatment-resistant depression.
Medical Mythbusting Commentary for November 2, 2026 Source:A fast-acting nasal spray offers hope for hard-to-treat depression: study Reference:Single Intranasal Administration of the Psychedelic Mebufotenin for Treatment-Resistant Depression
-
New rapid five-day protocol application of transcranial magnetic stimulation brain for the treatment of treatment-resistant depression seems to be of equal efficacy of the standard six- week treatment cycle.
Medical Mythbusting Commentary for February 26, 2026 Source:New brain stimulation approach could treat depression in just 5 days Reference:Efficacy of 5 × 5 accelerated versus conventional repetitive transcranial magnetic stimulation (rTMS) for treatment-resistant depression.